|
Market Closed -
London S.E.
16:35:16 02/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1355 GBX | -3.21% |
|
+0.37% | -46.86% |
| 09-22 | WINNERS & LOSERS: Petro Matad sinks on PetroChina blow; Midwich up | AN |
| 09-14 | WINNERS & LOSERS: Tribal to sell assets; Brave Bison ups System1 tilt | AN |
| Market Cap | 3.78M 5.01M 4.45M 4.15M 7.14M 481M 7.2M 50.24M 19.47M 246M 18.8M 18.39M 790M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.69M 4.88M 4.33M 4.04M 6.95M 469M 7.02M 48.95M 18.97M 240M 18.31M 17.91M 769M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 day | -3.21% | ||
| 1 week | +0.37% | ||
| Current month | -6.55% | ||
| 1 month | -17.88% | ||
| 3 months | -24.72% | ||
| 6 months | -22.57% | ||
| Current year | -46.86% |
| 1 week | 0.13 |  | 0.16 |
| 1 month | 0.13 | | 0.17 |
| Current year | 0.12 | | 0.4 |
| 1 year | 0.12 | | 0.56 |
| 3 years | 0.04 | | 0.56 |
| 5 years | 0.04 | | 1.93 |
| 10 years | 0.04 | | 14.89 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 28/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 30/06/2022 |
| Director/Board Member | 61 | 01/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 31/08/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/11/24 | Free | Director | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Chairman | 22,000,000 | 2.6852% | ||
| 05/11/24 | Free | Founder | 12,000,000 | 1.4646% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.21% | +0.37% | -43.54% | -48.48% | 4.68M | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -1.01% | -3.02% | +19.11% | +48.17% | 369.72B | |
| Weighted average by Cap. | -0.60% | -3.33% | +29.07% | +71.15% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.82M -4.28M -4M -6.87M -463M -6.93M -48.35M -18.74M -237M -18.09M -17.7M -760M | -653K -863K -767K -716K -1.23M -83M -1.24M -8.66M -3.36M -42.43M -3.24M -3.17M -136M |
| Net Debt | -20.21K -26.74K -23.76K -22.17K -38.12K -2.57M -38.47K -268K -104K -1.31M -100K -98.21K -4.22M | -97.55K -129K -115K -107K -184K -12.41M -186K -1.3M -502K -6.34M -485K -474K -20.36M |
Employees
3
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/10/26 | GBX 0.1355 | -3.21% | 6,332,280 |
| 01/10/26 | GBX 0.1400 | -3.45% | 12,038,657 |
| 30/09/26 | GBX 0.1450 | 0.00% | 8,284,490 |
| 29/09/26 | GBX 0.1450 | -3.33% | 12,627,080 |
| 28/09/26 | GBX 0.1500 | +11.11% | 72,855,027 |
- Stock Market
- Stocks
- LVRT Stock
Select your edition
All financial news and data tailored to specific country editions
